Revvity reported third-quarter 2024 adjusted ... could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the ...

https://www.tipranks.com/news/the-fly/rallybio-price-target-lowered-to-7-from-8-at-jmp-securities Barclays analyst Luke Sergott lowered the firm’s price target on ...

Revvity, Inc. (NYSE: RVTY) announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a ...

Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development. Revvity cuts 2024 revenue forecast amid ...

Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening ...

Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Revvity in a research report issued on ...

Waltham, Massachusetts-based Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. Valued at ...

Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening ...

Stock analysts at Zacks Research lifted their FY2024 EPS estimates for shares of Revvity in a report issued on Monday, ...